宫颈癌单次置入多分次图像引导自适应高剂量率近距离放疗:剂量学与临床结局
一项前瞻性2期研究纳入41例IIB-IVA期宫颈癌患者,评估单次置入多分次高剂量率图像引导自适应近距离放疗的可行性与安全性。
要点
- 单次置入多分次高剂量率图像引导自适应近距离放疗在95%患者中可行。
- 高危临床靶区D90平均87.2±3.6 Gy,2年局部控制率90.1%。
- 2年总生存率94.5%,报告1例II级和2例III级直肠毒性。
核心结论
- 磁共振图像引导自适应近距离放疗联合单次置入多分次方案在95%患者中可行。
- 剂量学参数和临床结果看起来有前景。
研究设计与样本
- 前瞻性2期研究,纳入41例国际妇产科联盟2009分期IIB-IVA期宫颈癌患者,2017至2019年入组。
- 外照射放疗50 Gy/25次后行磁共振图像引导自适应近距离放疗,采用单次置入多分次高剂量率方案。
- 近距离放疗方案为单次置入,第1天9 Gy,第2天7 Gy两次(间隔至少6小时),共3次。
- 第2天第二次分次前行CT计划及基于互信息坐标系统的配准以处理分次间变化。
主要发现
- 所有患者接受腔内联合组织间插植近距离放疗,中位插植针数4根(范围3-11)。
- 高危临床靶区体积平均41±21 cm3,D90剂量平均87.2±3.6 Gy。
- 膀胱0.1 cm3和2 cm3剂量分别为-103.2±10.6 Gy和-84.6±6.8 Gy;直肠分别为82.2±9.5 Gy和-68.3±5.7 Gy;乙状结肠分别为83.5±9.8 Gy和-69.5±5.9 Gy。
- 6例患者在第二次分次前需要重新优化以满足计划目标。
- 中位随访22个月(范围2-37),2年局部控制率90.1%、无病生存率85%、总生存率94.5%。
关键数值与推荐
- 高危临床靶区计划目标为EQD2>84 Gy。
- 膀胱2 cm3计划目标为≤85 Gy。
- 直肠/乙状结肠2 cm3计划目标为<71 Gy。
临床怎么用
- 宫颈癌根治性放疗中外照射后可采用单次置入多分次高剂量率图像引导自适应近距离放疗。
- 第2天分次前应行CT计划和配准评估分次间变化,必要时重新优化以满足剂量目标。
局限性
- 中位随访仅22个月,长期疗效和毒性尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A prospective phase 2 study was conducted to evaluate the feasibility and safety of single-application multifractionated (SA-MF), high-dose-rate (HDR), image guided adaptive brachytherapy (IGABT) for cervical cancer. METHODS AND MATERIALS: Patients (N = 41) with International Federation of Gynaecology and Obstetrics 2009 stage IIB-IVA disease recruited between 2017 and 2019 underwent SA-MF. After completion of external beam radiation therapy of 50 Gy in 25 fractions, patients received magnetic resonance IGABT. The IGABT protocol consisted of a single brachytherapy (BT) application and treatment with 3 fractions of HDR (9 Gy on day 1; 2 fractions of 7 Gy with a minimum 6-hour gap on day 2) after achieving planning aims of the high-risk clinical target volume (HRCTV) receiving >84 Gy EQD2 and 2 cm3 of the bladder and rectum/sigmoid receiving ≤85 Gy and <71 Gy, respectively. Interfraction variation was addressed by performing computed tomography planning and coregistration using a mutual information-based coordinate system on day 2 before the second fraction. Organ at risk contouring was done on computed tomography, and doses were re-evaluated and reoptimized if required. RESULTS: Thirty-eight patients were treated as per the protocol. All patients underwent Intracavitary + Interstitial BT with needles (median, 4; range, 3-11). The mean ± standard deviation HRCTV volume was 41 ± 21 cm3 and HRCTV D90 dose was 87.2 ± 3.6Gy. The 0.1 cm3 and 2 cm3 to bladder, rectum, and sigmoid were -103.2 ± 10.6 Gy and -84.6 ± 6.8 Gy, 82.2 ± 9.5 Gy and -68.3 ± 5.7 Gy, and 83.5 ± 9.8 Gy and -69.5 ± 5.9 Gy, respectively. Six patients required reoptimization before the second fraction to meet planning aims. Mean overall treatment time was 47 ± 6 days. With a median follow up of 22 months (range, 2-37), 2-year local control and disease-free and overall survival were 90.1%, 85%, and 94.5%, respectively. So far 1 patient with grade II and 2 patients with grade III rectal toxicities have been reported. CONCLUSION: Magnetic resonance IGABT with SA-MF BT was feasible in 95% of patients. The dosimetric parameters and clinical results achieved so far look promising.
引用
- Mahantshetty U, Gurram L, Bushra S, et al. Single Application Multifractionated Image Guided Adaptive High-Dose-Rate Brachytherapy for Cervical Cancer: Dosimetric and Clinical Outcomes. Int J Radiat Oncol Biol Phys. 2021. PMID: 34146636. doi:10.1016/j.ijrobp.2021.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。